美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.36

+0.10590.31%

盤後：34.360.0041+0.01%16:15 EDT

成交量：1.97萬

成交額：67.69萬

市值：9,550.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.95

換手率：0.71%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

中國生物製藥：本集團附屬公司正大天晴藥業集團股份有限公司自主研發的國家 1 類創新藥 TQB2102 注射液「HER2

百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進

Contineum 股價下跌 9.9%，原因是其與強生合作研發的抗抑鬱藥中期臨床試驗失敗。

吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章

吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及

吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。

吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致

吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性

吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平

吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市

市場消息：美國食品藥品監督管理局啓動加速新藥臨床試驗申請試點項目，開始受理相關申請。

石藥創新：SYS6010再獲突破性治療認定 III期臨床試驗正在開展

創新藥「一日遊」？華寶基金藥ETF、港股通創新藥ETF雙雙回調！基本面仍有支撐：數據讀出+出海邏輯持續驗證

恒瑞醫藥：子公司「注射用瑞卡西單抗」獲批開展III期臨床試驗

恒瑞醫藥(600276.SH)：HRS-4139片獲得藥物臨床試驗批准通知書

恒瑞醫藥：子公司HRS-4139片獲臨床試驗批准

恒瑞醫藥：瑞卡西單抗獲批開展III期臨床試驗

維康藥業(300878.SZ)：黃甲軟肝顆粒獲批開展用於慢性乙型病毒性肝炎肝纖維化的III期臨床試驗

維康藥業：黃甲軟肝顆粒獲III期臨床試驗補充申請批准

興齊眼藥(300573.SZ)：SQ-25012注射液獲得臨床試驗批准通知書

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19671,"hourTrading":{"tag":"盘后","latestPrice":34.36,"preClose":34.3559,"latestTime":"16:15 EDT","volume":44,"amount":1508.319428,"timestamp":1789589700352,"change":0.0041,"changeRate":0.000119,"amplitude":0.010187},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":0.1059,"latestTime":"09-16 17:53:19 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":676854,"amplitude":0.012286,"askPrice":34.72,"askSize":8201,"bidPrice":34.35,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.76286,"aum":96640785.56286,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.36,"preClose":34.3559,"latestTime":"16:15 EDT","volume":44,"amount":1508.319428,"timestamp":1789589700352,"change":0.0041,"changeRate":0.000119,"amplitude":0.010187},"volumeRatio":0.94973,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.94973,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"committee":-0.999756,"eps":0,"divideRate":0.007478,"volume":19671,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667530620","title":"中國生物製藥：本集團附屬公司正大天晴藥業集團股份有限公司自主研發的國家 1 類創新藥 TQB2102 注射液「HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2667530620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667530620?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 07:10","pubTimestamp":1789513851,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667629132","title":"百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進","url":"https://stock-news.laohu8.com/highlight/detail?id=2667629132","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667629132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 01:29","pubTimestamp":1789493363,"startTime":"0","endTime":"0","summary":"百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进Blake Brittain路透9月15日-百时美施贵宝公司和小野制药公司已在特拉华州联邦法院起诉安进公司，试图阻止安进公司在美国推出其畅销癌症免疫疗法药物“欧迪沃”的生物类似药。百时美施贵宝和小野制药的发言人尚未立即回应置评请求。共同开发“欧狄沃”的百时美施贵宝和小野制药指控，安进的生物类似药将侵犯该药物所涉及的七项美国专利，并请求法院在专利有效期内禁止该生物类似药的销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T4571DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","PBE","BK4585","AMGN","LU1670711040.USD","LU0432979614.USD","LU0320765992.SGD","IBB","LU1989771016.USD","LU0456855351.SGD","LU0889565916.HKD","LU0225284248.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","PJP","LU1074936037.SGD","LU2468319806.SGD","IE0002141913.USD","BK4139","BK4533","BK4559","LU2242646821.SGD","04332","LU1093756325.SGD","LU1868836757.USD","LU2089984988.USD","BK4534","BK4588","LU1571399168.USD","BMY","LU0289739699.SGD","IE00BFXG1179.USD","IE00BSNM7G36.USD","BK4007","LU2133065610.SGD","LU0306807586.USD","LU0321505868.SGD","LU0096364046.USD","LU0321505439.SGD","LU0109394709.USD","LU1670710661.SGD","BK4532","LU0237698245.USD","LU0114720955.EUR","LU1236620750.USD","LU1585245621.USD","LU0882574055.USD","LU0225771236.USD","LU1291159041.SGD","BK4581","LU1093756168.USD","LU1236620834.HKD","LU0306806265.USD","LU1032466523.USD","LU1868837300.USD","LU0061475181.USD","LU1718418525.SGD","LU0122379950.USD","LU2360032135.SGD","LU1868836591.USD","LU1261432733.SGD","LU2125154935.USD","LU1057294990.SGD","LU0985481810.HKD","BIB","LU0058720904.USD","IE00B2B36J28.USD","IBBQ","LU2596442595.SGD","LU0267386448.USD","LU1023059063.AUD","LU2125154778.USD","LU1670710588.SGD","LU2242652126.USD","LU1061106388.HKD","LU1323610961.USD","IE00BFTCPJ56.SGD","LU1868836914.USD","LU1883839398.USD","IE00BJT1NW94.SGD","LU1868837136.USD","LU1430594728.SGD","LU1670711123.USD","BBH","FTXH","SG9999001440.SGD","IE0009355771.USD","LU2112291526.USD","LU0868494617.USD","BK4566","TBXU","LU1983299246.USD","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667296846","title":"Contineum 股價下跌 9.9%，原因是其與強生合作研發的抗抑鬱藥中期臨床試驗失敗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667296846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667296846?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 01:17","pubTimestamp":1789492646,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0124676726.USD","IXJ","JNJ","LU1244550577.SGD","LU0345769631.USD","LU1629891620.HKD","LU1162221912.USD","IHE","LU0792757196.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","FTXH","GDOC","VHT","IE00BFXG1179.USD","IBBQ","LU1032955483.USD","RXL","BK4568","IBBJ","FHLC","XLV","IE000SO60NU8.SGD","IE00BFTCPJ56.SGD","LU0545562505.USD","BMED","LU0203345920.USD","LU1430594728.SGD","LU1585245621.USD","MEDX","LU0432979614.USD","TRUH","IYH","LU2403377893.USD","LU0820561818.USD","LU1674673691.USD","LU2417539215.USD","LU0072461881.USD","LU0289739699.SGD","PJP","PSYK","LU0689626769.HKD","MDTX","IE00BJT1NW94.SGD","IE00B42XCP33.USD","LU0889566641.SGD","LU1989771016.USD","LU1929549753.HKD","LU1228905540.USD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","SG9999015952.SGD","BIB","BK4550","LU1585245621.USD","BK4568","BMED","LU0882574055.USD","LU1061106388.HKD","LU1934455194.USD","BK4566","LU1934455277.USD","SG9999015978.USD","TMED","LU0823416689.USD","LU0861579265.USD","BK4585","LU2087621335.USD","LU0965509283.SGD","LU1023059063.AUD","LU0889565916.HKD","LU1839511570.USD","LU1674673428.USD","BK4532","LU0058720904.USD","LU2468319806.SGD","IBB","IE00B7SZLL34.SGD","LU1934455863.HKD","LU0122379950.USD","LU0965509010.AUD","LU1430594728.SGD","SG9999015945.SGD","BK4139","LU1037948897.HKD","LU2324357040.USD","LU2357627491.SGD","MEDI","LU0965509101.SGD","LU1674673691.USD","LU2112291526.USD","LU0114720955.EUR","BK4588","LU1778281490.HKD","IE00B19Z3B42.SGD","LU1037948541.HKD","TBXU","IE0002270589.USD","LU1066053197.SGD","LU0965508806.USD","BBH","IBBQ","BK4583","LU1571399168.USD","GILD","LU1057294990.SGD","SG9999015986.USD","LU1066051498.USD","LU0289739699.SGD","IE00B3T34201.USD","LU0320765992.SGD","LU2089984988.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","BK4578","IE00B19Z3581.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU0861579265.USD","LU1571399168.USD","LU1674673691.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","MEDI","IE00BSNM7G36.USD","LU1839511570.USD","IBBQ","TMED","LU1778281490.HKD","BK4583","IE00B19Z3B42.SGD","BBH","LU2468319806.SGD","TBXU","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1061106388.HKD","LU1066051498.USD","LU0320765992.SGD","IBB","LU1037948541.HKD","BK4578","LU2112291526.USD","LU0058720904.USD","SG9999015978.USD","IE00BKVL7J92.USD","BK4566","BMED","LU0965508806.USD","LU0965509283.SGD","LU1023059063.AUD","LU1585245621.USD","LU1934455194.USD","LU0114720955.EUR","BIB","LU0859254822.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","LU0965509010.AUD","BK4550","LU2089984988.USD","LU0122379950.USD","BK4139","BK4568","IE00B3T34201.USD","LU0109394709.USD","LU0234570918.USD","SG9999015986.USD","LU2357627491.SGD","LU1934455277.USD","LU1037948897.HKD","LU0289739699.SGD","LU2087621335.USD","LU1934455863.HKD","BK4532","LU2324357040.USD","LU0823416689.USD","IE0002270589.USD","GILD","SG9999015945.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623020","title":"吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623020","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:11","pubTimestamp":1789485099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0859254822.USD","IE0002270589.USD","TBXU","BK4550","LU1057294990.SGD","LU1066051498.USD","LU1839511570.USD","IBBQ","LU0234570918.USD","LU0965509283.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","LU2112291526.USD","SG9999015978.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU1934455277.USD","BK4532","LU2324357040.USD","LU0289739699.SGD","BMED","BK4566","IBB","BK4568","LU0965509101.SGD","BIB","LU1066053197.SGD","BK4139","GILD","LU1037948897.HKD","LU1585245621.USD","LU1674673691.USD","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LU1674673428.USD","TMED","LU0114720955.EUR","SG9999015952.SGD","LU1061106388.HKD","LU1037948541.HKD","SG9999015945.SGD","LU0965509010.AUD","BK4588","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","MEDI","BBH","LU1430594728.SGD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062306","title":"吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062306","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062306?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485029,"startTime":"0","endTime":"0","summary":"吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致路透9月15日-美国制药公司吉利德科学GILD.O周二表示，已与泛美卫生组织达成协议，将在拉丁美洲和加勒比地区扩大其艾滋病预防药物的可及性，以帮助这些地区遏制新发感染。吉利德公司指出，2010年至2024年间，拉丁美洲和加勒比地区的新发艾滋病毒感染病例增加了13%，并归因于艾滋病毒预防药物使用方面的缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T45714A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","BK4568","LU2324357040.USD","MEDI","BK4139","LU0965509010.AUD","LU1057294990.SGD","BK4550","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1585245621.USD","TBXU","LU1066051498.USD","BBH","IE00BKVL7J92.USD","LU0058720904.USD","IE0002270589.USD","IBB","LU1037948897.HKD","LU0859254822.USD","SG9999015945.SGD","LU0122379950.USD","SG9999015952.SGD","LU1934455277.USD","SG9999015978.USD","LU0965509101.SGD","LU2112291526.USD","LU0965509283.SGD","LU0889565916.HKD","LU1934455863.HKD","LU0320765992.SGD","IBBQ","TMED","LU1674673691.USD","BMED","IE00B19Z3581.USD","BK4588","LU1037948541.HKD","LU1839511570.USD","BIB","LU0882574055.USD","LU1066053197.SGD","GILD","BK4532","LU0234570918.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU0289739699.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU0861579265.USD","LU1571399168.USD","LU1674673691.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","MEDI","IE00BSNM7G36.USD","LU1839511570.USD","IBBQ","TMED","LU1778281490.HKD","BK4583","IE00B19Z3B42.SGD","BBH","LU2468319806.SGD","TBXU","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1061106388.HKD","LU1066051498.USD","LU0320765992.SGD","IBB","LU1037948541.HKD","BK4578","LU2112291526.USD","LU0058720904.USD","SG9999015978.USD","IE00BKVL7J92.USD","BK4566","BMED","LU0965508806.USD","LU0965509283.SGD","LU1023059063.AUD","LU1585245621.USD","LU1934455194.USD","LU0114720955.EUR","BIB","LU0859254822.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","LU0965509010.AUD","BK4550","LU2089984988.USD","LU0122379950.USD","BK4139","BK4568","IE00B3T34201.USD","LU0109394709.USD","LU0234570918.USD","SG9999015986.USD","LU2357627491.SGD","LU1934455277.USD","LU1037948897.HKD","LU0289739699.SGD","LU2087621335.USD","LU1934455863.HKD","BK4532","LU2324357040.USD","LU0823416689.USD","IE0002270589.USD","GILD","SG9999015945.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","LU0058720904.USD","BK4139","BIB","LU0965509283.SGD","TBXU","LU2324357040.USD","BK4550","IE00BSNM7G36.USD","LU0114720955.EUR","LU0234570918.USD","LU0289739699.SGD","LU1571399168.USD","IE00B7SZLL34.SGD","LU1066051498.USD","LU1037948541.HKD","LU0122379950.USD","LU1430594728.SGD","SG9999015986.USD","LU1061106388.HKD","LU0965508806.USD","LU2357627491.SGD","BK4578","BK4566","IE00B19Z3B42.SGD","LU0109394709.USD","LU1585245621.USD","SG9999015978.USD","BBH","LU1674673691.USD","LU1023059063.AUD","LU1066053197.SGD","LU0889565916.HKD","LU1934455277.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4532","BK4568","LU0320765992.SGD","LU1057294990.SGD","LU0861579265.USD","LU1934455194.USD","IE00B3T34201.USD","LU0823416689.USD","IBB","LU1674673428.USD","LU1934455863.HKD","BK4588","IE00B19Z3581.USD","LU2087621335.USD","LU2112291526.USD","LU2468319806.SGD","SG9999015952.SGD","BMED","IE0002270589.USD","LU1037948897.HKD","IBBQ","LU0882574055.USD","LU0965509010.AUD","SG9999015945.SGD","TMED","BK4585","BK4583","LU1839511570.USD","MEDI","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667362891","title":"市場消息：美國食品藥品監督管理局啓動加速新藥臨床試驗申請試點項目，開始受理相關申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667362891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667362891?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:09","pubTimestamp":1789481392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667264193","title":"石藥創新：SYS6010再獲突破性治療認定 III期臨床試驗正在開展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667264193","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667264193?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:08","pubTimestamp":1789470480,"startTime":"0","endTime":"0","summary":"中证智能财讯石药创新(300765)9月15日晚间公告，公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBJ","BK0226","MDTX","300765","IBBQ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667964132","title":"創新藥「一日遊」？華寶基金藥ETF、港股通創新藥ETF雙雙回調！基本面仍有支撐：數據讀出+出海邏輯持續驗證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667964132","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667964132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:04","pubTimestamp":1789470240,"startTime":"0","endTime":"0","summary":"逆市大涨之后，9月15日，A+H创新药短线迎来回调，药ETF华宝、港股通创新药ETF华宝标的指数分别收跌0.8%、1.48%。创新药龙头数据读出。出海逻辑持续验证。逢跌埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-15/doc-inirxhzq8476737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","BK1574","159316","BK4588","159992","BK1161","MEDX","06978","FLHK","FDN","LNGR","BK4585","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648964","title":"恒瑞醫藥：子公司「注射用瑞卡西單抗」獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648964","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648964?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:55","pubTimestamp":1789462500,"startTime":"0","endTime":"0","summary":"9月15日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司近日收到国家药品监督管理局核准签发的关于注射用瑞卡西单抗的《药物临床试验批准通知书》，将于近期开展III期临床试验。该药物的适应症为颅内动脉粥样硬化性狭窄的成人患者，以降低卒中复发风险。2026年中期，恒瑞医药实现收入154.56亿元，归母净利润44.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874740380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874740380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0060","BK1191","LU1064131003.USD","LU2328871848.SGD","BMED","LU2580892862.HKD","LU1580142542.USD","LU2289578879.USD","BK0183","LU0405327148.USD","LU2097828557.USD","LU1023057109.AUD","LU0405327494.USD","LU1997245094.SGD","LU2148510915.USD","MDTX","LU2580892789.USD","LU2543165471.USD","BK0012","LU2488822045.USD","LU2097828474.EUR","01276","LU2495084118.USD","LU1255011170.USD","IBBJ","IBBQ","LU1820825898.SGD","LU1655091616.SGD","LU1997245177.USD","LU2097828714.EUR","LU1064130708.USD","BK0188","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU0359201612.USD","LU1997244956.HKD","LU1146622755.USD","LU0359202008.SGD","LU1969619763.USD","PSYK","LU1328615791.USD","LU2097828631.EUR","BK0028","600276","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610471","title":"恒瑞醫藥(600276.SH)：HRS-4139片獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610471","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667610471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:39","pubTimestamp":1789461583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4139片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-4139片是公司自主研发的1类新药，在动物模型中，可有效改善银屑病症状，抑制炎症反应。经查询，国内外暂无相同靶点药物获批上市。截至目前，HRS-4139片相关项目累计研发投入约2,040万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU1997244956.HKD","BMED","BK1191","LU1146622755.USD","LU2097828474.EUR","LU2495084118.USD","LU1064130708.USD","LU2097828714.EUR","BK0012","LU0405327494.USD","LU1064131003.USD","LU2328871848.SGD","LU2148510915.USD","LU2488822045.USD","LU1655091616.SGD","LU2097828631.EUR","BK0060","LU0405327148.USD","LU1781817850.SGD","LU2289578879.USD","LU1023057109.AUD","BK0196","LU2580892789.USD","IBBQ","LU2097828557.USD","PSYK","LU1997245094.SGD","LU1997245177.USD","IBBJ","01276","LU0359202008.SGD","LU2543165471.USD","LU1820825898.SGD","LU1328615791.USD","600276","BK0239","MDTX","LU2580892862.HKD","LU1580142542.USD","BK0028","LU2097828805.USD","LU1969619763.USD","BK0183","LU0359201885.HKD","LU1255011170.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610193","title":"恒瑞醫藥：子公司HRS-4139片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667610193?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:35","pubTimestamp":1789461321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","BMED","IBBJ","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667101906","title":"恒瑞醫藥：瑞卡西單抗獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667101906","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667101906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:35","pubTimestamp":1789461310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","IBBQ","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667832610","title":"維康藥業(300878.SZ)：黃甲軟肝顆粒獲批開展用於慢性乙型病毒性肝炎肝纖維化的III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667832610","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667832610?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:15","pubTimestamp":1789460131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的黄甲软肝颗粒的《药物临床试验补充申请批准通知书》，经审查，黄甲软肝颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于慢性乙型病毒性肝炎肝纤维化的III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","IBBJ","IBBQ","BK0239","300878","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661724","title":"維康藥業：黃甲軟肝顆粒獲III期臨床試驗補充申請批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661724?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:07","pubTimestamp":1789459662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617527","title":"興齊眼藥(300573.SZ)：SQ-25012注射液獲得臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617527","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:54","pubTimestamp":1789458841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-25012注射液的《药物临床试验批准通知书》，同意本品开展拟用于治疗甲状腺眼病的临床试验。SQ-25012注射液是一款重组人源化IgG1型三特异性抗体，为公司研发的治疗用生物制品1类创新药，临床拟用于治疗甲状腺眼病。根据创新型治疗用生物制品1类注射剂的有关要求，公司已经完成SQ-25012注射液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-25012注射液具有良好的安全性及临床开发价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","BMED","IBBQ","PSYK","MDTX","IBBJ","300573","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":2,"totalSize":214,"code":"91000000","status":"200"}]}}